menu
    • menu

    Company profile for Diamyd Medical AB

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development. Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®. Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells. Diamyd® and Remygen® are current...
    Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development. Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®. Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells. Diamyd® and Remygen® are currently being evaluated in clinical trials. Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Diamyd Medical ABSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Kungsgatan 29, SE-111 56 Stockholm, Sweden
    Telephone
    Telephone
    +46 8 661 00 26
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.diamyd.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Diamyd Secures Expanded Financial Support From Breakthrough T1D
    Diamyd Secures Expanded Financial Support From Breakthrough T1D

    12 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-announces-expanded-financial-support-from-breakthrough-t1d-302374634.html

    PR NEWSWIRE
    12 Feb 2025
    Share Share
    Diamyd Medical updates U.S. market potential for Diamyd®
    Diamyd Medical updates U.S. market potential for Diamyd®

    13 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-updates-us-market-potential-for-diamyd-302349066.html

    PR NEWSWIRE
    13 Jan 2025
    Share Share
    Diamyd Medical Advances Toward Accelerated Approval for Diamyd
    Diamyd Medical Advances Toward Accelerated Approval for Diamyd

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd-following-fda-type-c-meeting-302347893.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    Diamyd Aligns With FDA On Accelerated Approval Key Points
    Diamyd Aligns With FDA On Accelerated Approval Key Points

    13 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-aligns-with-fda-on-key-elements-for-an-accelerated-approval-process-302331214.html

    PR NEWSWIRE
    13 Dec 2024
    Share Share
    Diamyd Medical Reaches Recruitment Milestone in DIAGNODE-3 Phase 3
    Diamyd Medical Reaches Recruitment Milestone in DIAGNODE-3 Phase 3

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial-302312971.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    Diamyd® Gets Second FDA Fast Track For Type 1 Diabetes Prevention
    Diamyd® Gets Second FDA Fast Track For Type 1 Diabetes Prevention

    17 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-receives-second-us-fda-fast-track-designation-for-diamyd---for-the-prevention-of-type-1-diabetes-302200410.html

    PR NEWSWIRE
    17 Jul 2024
    Share Share

    ABOUT THIS PAGE

    Contact Diamyd Medical AB and get a quotation

    Diamyd Medical AB is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of RECOMBINANT HUMAN GLUTAMIC ACID DECARBOXYLASE (RHGAD65) bulk offered by Diamyd Medical AB

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search